IL164779A0 - Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders - Google Patents

Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders

Info

Publication number
IL164779A0
IL164779A0 IL16477904A IL16477904A IL164779A0 IL 164779 A0 IL164779 A0 IL 164779A0 IL 16477904 A IL16477904 A IL 16477904A IL 16477904 A IL16477904 A IL 16477904A IL 164779 A0 IL164779 A0 IL 164779A0
Authority
IL
Israel
Prior art keywords
disorders
oculat
affective
tinnitus
myopia
Prior art date
Application number
IL16477904A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209889A external-priority patent/GB0209889D0/en
Priority claimed from GB0209886A external-priority patent/GB0209886D0/en
Priority claimed from GB0209887A external-priority patent/GB0209887D0/en
Priority claimed from GB0210371A external-priority patent/GB0210371D0/en
Priority claimed from GB0212760A external-priority patent/GB0212760D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL164779A0 publication Critical patent/IL164779A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16477904A 2002-04-30 2004-10-21 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders IL164779A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0209889A GB0209889D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0209886A GB0209886D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0209887A GB0209887D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0210371A GB0210371D0 (en) 2002-05-07 2002-05-07 Organic compounds
GB0212760A GB0212760D0 (en) 2002-05-31 2002-05-31 Organic compounds
PCT/EP2003/004466 WO2003092701A2 (en) 2002-04-30 2003-04-29 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders

Publications (1)

Publication Number Publication Date
IL164779A0 true IL164779A0 (en) 2005-12-18

Family

ID=29408096

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16477904A IL164779A0 (en) 2002-04-30 2004-10-21 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders

Country Status (13)

Country Link
US (1) US20060293282A1 (de)
EP (1) EP1501518A2 (de)
JP (2) JP2005527600A (de)
KR (1) KR20040101573A (de)
CN (1) CN1649599A (de)
BR (1) BR0309611A (de)
CA (1) CA2482524A1 (de)
IL (1) IL164779A0 (de)
MX (1) MXPA04010816A (de)
NO (1) NO20045089L (de)
PL (1) PL371427A1 (de)
TW (1) TW200403066A (de)
WO (1) WO2003092701A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0310868D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
GB0324542D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0324541D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325172D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
AU4423496A (en) * 1995-03-14 1996-10-02 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9604400D0 (en) * 1996-03-01 1996-05-01 Pfizer Ltd Compounds useful in therapy
US6191134B1 (en) * 1996-06-05 2001-02-20 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
CA2269807C (en) * 1996-10-24 2007-04-10 Novartis Ag Substituted aminoalkanephosphonic acids
SE508138C2 (sv) * 1996-12-20 1998-08-31 Ericsson Telefon Ab L M Metod och anordning för anslutning av elektrisk komponent till kretskort
GB9802225D0 (en) * 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
US6291479B1 (en) * 1998-12-03 2001-09-18 Alcon Manufacturing, Ltd. Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法

Also Published As

Publication number Publication date
JP2009137995A (ja) 2009-06-25
WO2003092701A2 (en) 2003-11-13
PL371427A1 (en) 2005-06-13
NO20045089L (no) 2004-11-23
BR0309611A (pt) 2005-02-09
KR20040101573A (ko) 2004-12-02
MXPA04010816A (es) 2005-03-07
CA2482524A1 (en) 2003-11-13
WO2003092701A3 (en) 2004-04-08
EP1501518A2 (de) 2005-02-02
US20060293282A1 (en) 2006-12-28
JP2005527600A (ja) 2005-09-15
TW200403066A (en) 2004-03-01
CN1649599A (zh) 2005-08-03
AU2003232224A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
AU2003286567A8 (en) Methods for the treatment of skin disorders
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
EP1509279A4 (de) Vorrichtung und verfahren zur behandlung von herzkrankheiten
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AU2003300791A1 (en) Combination therapy for the treatment of pain
IL164779A0 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other oculat disorders
GB0213869D0 (en) The treatment of pain
GB0128674D0 (en) Treatment of sleep disorders and the like
EP1660101A4 (de) Flüssige formulierungen zur prävention und behandlung von schleimhauterkrankungen und störungen
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
PL376756A1 (pl) Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych
EP1539100A4 (de) Zusammensetzung und verfahren zur behandlung von hauterkrankungen
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
IL162053A0 (en) Method for the treatment of bone disorders
AU2003290970A8 (en) Compositions and method for treating affective, painful or allergic disorders
HK1073254A (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
AU2003229255A1 (en) Method of diagnosis and treatment for affective disorders
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
EP1440169A4 (de) Verfahren und zusammensetzungen zur behandlung und diagnose von schmerzspezifischen störungen unter verwendung von 57749